Microbot Medical Announces Successful Initial Outcomes Of Using Its LIBERTY Robotic Surgical System In A Pivotal Pre-Clinical Study, With 100% Usability And Technical Success And No Observed Complications
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical Inc. (NASDAQ:MBOT) announced successful initial outcomes of using its LIBERTY Robotic Surgical System in a pivotal pre-clinical study. The study was conducted by three leading interventional radiologists and achieved 100% usability and technical success with no observed complications. The company plans to submit the Investigational Device Exemption (IDE) application to the FDA, pending the final report and completion of the verification and validation process.
October 17, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical's successful pre-clinical study of its LIBERTY Robotic Surgical System could potentially boost investor confidence in the company. Pending FDA approval, the system could provide a significant revenue stream for the company.
The successful pre-clinical study of Microbot Medical's LIBERTY Robotic Surgical System indicates the system's potential for successful application in clinical settings. This could boost investor confidence in the company's ability to deliver innovative and effective products. Pending FDA approval, the system could provide a significant revenue stream for the company, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100